Patent intelligence · US
US 11401267
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
Patent details — US 11401267
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 2, 2022
- Expiration
- Jul 28, 2042
- Applicant
- NURIX THERAPEUTICS, INC.
- Claims
- 32
- CPC classes
- A61P, A61P35/00, A61P37/00
Quick answer
US 11401267 (Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof) is held by NURIX THERAPEUTICS, INC.. Status: granted. Granted Aug 2, 2022. Expires Jul 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61P, A61P35/00, A61P37/00
More from NURIX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377106
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
granted -
US 12234230
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
granted -
US 12121540
CBL inhibitors and compositions for use in adoptive cell therapy
granted -
US 12091426
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
granted -
US 12049471
Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
granted -
US 12016860
Combination therapies with Cbl-b inhibitor compounds
granted -
US 11951133
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
granted -
US 11866442
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted
Frequently asked questions
What is US patent 11401267?
US 11401267 (Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof) is held by NURIX THERAPEUTICS, INC.. Status: granted. Granted Aug 2, 2022. Expires Jul 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11401267?
NURIX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11401267 expire?
Our index shows an expiration date of Jul 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.